1xbet 우회

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Denka Company, Limited (Denka) announce that on June 16, Denka received manufacturing and marketing approval in Japan for Quick Navi ™ -Flu + COVID-19 Ag. This antigen rapid diagnostic kit enables medical professionals to simultaneously diagnose influenza and Covid-19. It is t1xbet 우회 latest product in t1xbet 우회 QuickNavi^TM series of in vitro diagnostics. T1xbet 우회 combo kit is to be manufactured in Japan by Denka and will be co-marketed in t1xbet 우회 country by Denka and Otsuka.　

In t1xbet 우회 past, it was necessary to test separately for t1xbet 우회 Covid-19 and influenza, but with this combination kit, t1xbet 우회 burdens of sample-taking, t1xbet 우회 time required for sample assessment, and t1xbet 우회 wait-time for review by a medical professional can be reduced.

This combination diagnosis kit reduces from a total of 15 minutes to a total of 10 minutes t1xbet 우회 assessment time for t1xbet 우회 presence or absence of a specific Covid-19 antigen.